Sandbox/AL: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 7: Line 7:
! style="background: #4479BA; color:#FFF;  width: 350px;" | Prophylaxis
! style="background: #4479BA; color:#FFF;  width: 350px;" | Prophylaxis
! style="background: #4479BA; color:#FFF;  width: 350px;" | Treatment
! style="background: #4479BA; color:#FFF;  width: 350px;" | Treatment
|-
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | Pneumocystis Pneumonia
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | Toxoplasma gondii Encephalitis
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | Cryptosporidiosis
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | Microsporidiosis
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | Mycobacterium tuberculosis
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |  
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |  
Line 20: Line 57:
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" colspan=5| Table adapted from Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents <ref>{{cite web| url=http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5804a1.htm| title=Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents}} </ref>
|}
|}

Revision as of 19:50, 14 October 2014

Disease Clinical Findings Diagnosis Prophylaxis Treatment
Pneumocystis Pneumonia
Toxoplasma gondii Encephalitis
Cryptosporidiosis
Microsporidiosis
Mycobacterium tuberculosis
Table adapted from Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents [1]
  1. "Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents".